دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Flashback Foreword: Cisplatin/Pemetrexed in Non-Small-Cell Lung Cancer.
Stinchcombe, Thomas E. MD 1,2,
doi : 10.1200/JCO.22.02804
Volume 41(14) pgs. 2455-2669 May 10, 2023
JCO Flashback: Cisplatin Plus Gemcitabine Vs. Cisplatin Plus Pemetrexed-A Comparative Analysis (2008).
doi : 10.1200/JCO.23.00256
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer.
Scagliotti, Giorgio Vittorio; Parikh, Purvish; von Pawel, Joachim; Biesma, Bonne; Vansteenkiste, Johan; Manegold, Christian; Serwatowski, Piotr; Gatzemeier, Ulrich; Digumarti, Raghunadharao; Zukin, Mauro; Lee, Jin S.; Mellemgaard, Anders; Park, Keunchil; Patil, Shehkar; Rolski, Janusz; Goksel, Tuncay; de Marinis, Filippo; Simms, Lorinda; Sugarman, Katherine P.; Gandara, David
doi : 10.1200/JCO.22.02544
Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting.
Combined Programmed Death-Ligand 1 and MET Inhibition: Has Papillary Renal Cell Carcinoma MET Its Match?.
Brown, Jacqueline T. MD 1,2,; Nazha, Bassel MD, MPH 1,2,; Bilen, Mehmet Asim MD 1,2,
doi : 10.1200/JCO.22.02600
Shopping for New Cancer Screening Tests.
Etzioni, Ruth PhD 1,; Castle, Philip E. PhD 2
doi : 10.1200/JCO.23.00240
Examining Racial and Ethnic Inequities in Opioid Prescribing and Risk Screening Among Patients With Advanced Cancer.
Rodin, Rebecca A. MD, MSc 1; Smith, Cardinale B. MD, PhD 1,2,
doi : 10.1200/JCO.22.02879
Plasma Micro-RNA 371 Expression in Early-Stage Germ Cell Tumors: Are We Ready to Move Toward Biology-Based Decision Making?.
Alsyouf, Muhannad MD 1; Nappi, Lucia MD, PhD 2,; Nichols, Craig MD 2; Daneshmand, Siamak MD 1,
doi : 10.1200/JCO.22.02002
Clinical Uncertainties of Circulating Tumor DNA in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma in the Absence of National Comprehensive Cancer Network Guidelines.
Xie, Deborah X. MD 1; Kut, Carmen MD, PhD 2,; Quon, Harry MD, MS 2,; Seiwert, Tanguy Y. MD 3,; D'Souza, Gypsyamber PhD 4; Fakhry, Carole MD, MPH 1,
doi : 10.1200/JCO.22.00264
US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?.
Strohbehn, Garth W. MD, MPhil 1,2,3,4,; Lichter, Allen S. MD 4,; Ratain, Mark J. MD 4,5,6,7,
doi : 10.1200/JCO.22.02049
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
Suarez, Cristina MD 1,; Larkin, James M.G. MD 2,; Patel, Poulam MD 3,; Valderrama, Begona P. MD 4,; Rodriguez-Vida, Alejo MD, PhD 5,; Glen, Hilary MD 6,; Thistlethwaite, Fiona PhD 7,; Ralph, Christy MD 8,; Srinivasan, Gopalakrishnan MD 9; Mendez-Vidal, Maria Jose MD 10,; Hartmaier, Ryan MD 11,; Markovets, Aleksandra PhD 11,; Prendergast, Aaron MSc 12; Szabados, Bernadett MD 12,; Mousa, Kelly MSc 12,; Powles, Thomas MD, PhD 12,
doi : 10.1200/JCO.22.01414
Metastatic papillary renal cancer (PRC) has poor outcomes, and new treatments are required. There is a strong rationale for investigating mesenchymal epithelial transition receptor (MET) and programmed cell death ligand-1 (PD-L1) inhibition in this disease.
Data From a One-Stop-Shop Comprehensive Cancer Screening Center.
Bernstein, Ezra MD 1,2; Lev-Ari, Shahar PhD 1,3; Shapira, Shiran PhD 1,3; Leshno, Ari MD 1,3; Sommer, Udi PhD 4; Al-Shamsi, Humaid MD 5,; Shaked, Meital MD 1; Segal, Ori BA 1; Galazan, Lior BA 1; Hay-Levy, Mori BA 1; Sror, Miri MD 1; Harlap-Gat, Amira MD 1; Peer, Michael MD 1,3; Moshkowitz, Menachem MD 1,3; Wolf, Ido MD 1,3,6,; Liberman, Eliezer MD 1,3; Shenberg, Gil MD 1; Gur, Eyal MD 3,7; Elran, Hanoch MD 1,8; Melinger, Gustavo MD 3,9,; Mashiah, Jacob MD 3,10; Isakov, Ofer MD 3,11; Zrifin, Elad MD 1,12; Gluck, Nathan MD 3,11; Dekel, Roy MD 3,11; Kleinman, Shlomi MD 3,12; Aviram, Galit MD 3,13; Blachar, Arye MD 3,13; Kessler, Ada MD 3,13; Golan, Orit MD 3,13; Geva, Ravit MD 3,6,; Yossepowitch, Ofer MD 3,14; Neugut, Alfred I. MD 15,; Arber, Nadir MD, MSc, MHA 1,3,11,
doi : 10.1200/JCO.22.00938
Cancer is the second leading cause of death globally. However, by implementing evidence-based prevention strategies, 30%-50% of cancers can be detected early with improved outcomes.
Racial and Ethnic Disparities in Opioid Access and Urine Drug Screening Among Older Patients With Poor-Prognosis Cancer Near the End of Life.
Enzinger, Andrea C. MD 1,; Ghosh, Kaushik PhD 2; Keating, Nancy L. MD, MPH 3,4; Cutler, David M. PhD 2,3,5,6; Clark, Cheryl R. MD, ScD 4; Florez, Narjust MD 1; Landrum, Mary Beth PhD 3; Wright, Alexi A. MD, MPH 1
doi : 10.1200/JCO.22.01413
To characterize racial and ethnic disparities and trends in opioid access and urine drug screening (UDS) among patients dying of cancer, and to explore potential mechanisms.
High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors.
Stroot, Iris A.S. BSc 1,2; Brouwer, Jan BSc 1; Bart, Joost MD, PhD 3; Hollema, Harry MD, PhD 3; Stommel-Jenner, Denise J. MSc 4; Wagner, Marise M. MD, PhD 1; van Doorn, Helena C. MD, PhD 5; de Hullu, Joanne A. MD, PhD 6; Gaarenstroom, Katja N. MD, PhD 7; Beurden, Marc MD, PhD 8; van Lonkhuijzen, Luc R.C.W. MD, PhD 9; Slangen, Brigitte F.M. MD, PhD 10; Zweemer, Ronald P. MD, PhD 11; Gomez Garcia, Encarna B. MD, PhD 12; Ausems, Margreet G.E.M. MD, PhD 13,; Boere, Ingrid A. MD, PhD 14,; van Engelen, Klaartje MD, PhD 15; van Asperen, Christi J. MD, PhD 16; Schmidt, Marjanka K. PhD 4,16,17; Wevers, Marijke R. MD, PhD 18; de Bock, Geertruida H. PhD 2; Mourits, Marian J.E. MD, PhD 1,19,; on behalf of the HEBON Investigators
doi : 10.1200/JCO.22.01237
To investigate the prevalence of and clinical factors associated with high-grade serous carcinoma (HGSC) at risk-reducing salpingo-oophorectomy (RRSO) in asymptomatic BRCA1/2-pathogenic variant (PV) carriers
Long-Term Performance of an Image-Based Short-Term Risk Model for Breast Cancer.
Eriksson, Mikael PhD 1,; Czene, Kamila PhD 1,; Vachon, Celine PhD 2,; Conant, Emily F. MD 3,; Hall, Per MD, PhD 1,4,
doi : 10.1200/JCO.22.01564
Image-derived artificial intelligence-based short-term risk models for breast cancer have shown high discriminatory performance compared with traditional lifestyle/familial-based risk models. The long-term performance of image-derived risk models has not been investigated. METHODS
Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer.
Plichta, Jennifer K. MD, MS 1,2,3,; Thomas, Samantha M. MS 4,5; Hayes, Daniel F. MD 6,7,; Chavez-MacGregor, Mariana MD, MSc 8,9,; Allison, Kimberly MD 10,; de los Santos, Jennifer MD 11; Fowler, Amy M. MD, PhD 12,13,14,; Giuliano, Armando E. MD 15,; Sharma, Priyanka MD 16,; Smith, Benjamin D. MD 17,; van Eycken, Elizabeth MD 18,; Edge, Stephen B. MD 19,20,; Hortobagyi, Gabriel N. MD 21,
doi : 10.1200/JCO.22.02222
Given the heterogeneity and improvement in outcomes for metastatic breast cancer (MBC), we developed a staging system that refines prognostic estimates for patients with metastatic cancer at the time of initial diagnosis, de novo MBC (dnMBC), on the basis of survival outcomes and disease-related variables.
Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer.
Sanchez-Magraner, Lissete PhD 1,; Gumuzio, Juan PhD 1,; Miles, James PhD 1,; Quimi, Nicole MSc 1,; Martinez del Prado, Purificacion MD 2,; Abad-Villar, Maria Teresa MD 2; Pikabea, Fernando MD 2,; Ortega, Laura MD 2; Etxezarraga, Carmen MD 2; Martin-Algarra, Salvador MD 3,; Lozano, Maria D. MD 3,; Saiz-Camin, Monica MD 4; Egurrola-Izquierdo, Mikel MD 5; Barredo-Santamaria, Inmaculada MD 5; Saiz-Lopez, Alberto MD 5; Gomez-Mediavilla, Jenifer MD 6; Segues-Merino, Nerea MD 6; Juaristi-Abaunz, Maria Aranzazu MD 6; Urruticoechea, Ander MD 6,; Geraedts, Erica J. MD 7; van Elst, Kim MD 7; Claessens, Niels J.M. MD 8,; Italiano, Antoine MD 9,; Applebee, Christopher J. MSc 1; del Castillo, Sandra BSc 1,10,; Evans, Charles MSc 1,; Aguirre, Fernando MSc 1,; Parker, Peter J. PhD 1,11,12,; Calleja, Veronique PhD 1,
doi : 10.1200/JCO.22.01748
In many cancers, the expression of immunomodulatory ligands leads to immunoevasion, as exemplified by the interaction of PD-L1 with PD-1 on tumor-infiltrating lymphocytes.
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
Ding, Xi MD 1,2,3; Zhang, Wei-Jing MD 2,3,4; You, Rui MD, PhD 1,2,3; Zou, Xiong MD, PhD 1,2,3; Wang, Zhi-Qiang MD, PhD 5; Ouyang, Yan-Feng MD 1,2,3; Peng, Lan MD 1,2,3; Liu, You-Ping MD, PhD 1,2,3; Duan, Chong-Yang PhD 6; Yang, Qi MD, PhD 1,2,3; Lin, Chao MD 1,2,3; Xie, Yu-Long MD 1,2,3; Chen, Si-Yuan MD 1,2,3; Liu, Yong-Long MD 1,2,3; Gu, Chen-Mei BMan 1,2,3; Xie, Ruo-Qi MD 1,2,3; Huang, Pei-Yu MD, PhD 1,2,3; Hong, Ming-Huang MD, PhD 2,3,7; Hua, Yi-Jun MD, PhD 1,2,3; Chen, Ming-Yuan MD, PhD 1,2,3,
doi : 10.1200/JCO.22.01450
Immune checkpoint inhibitors combined with antiangiogenic therapy reportedly have potential synergistic antitumor activity. We investigated the activity and safety of this regimen for recurrent/metastatic nasopharyngeal carcinoma (NPC).
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase II Trial.
Xia, Jieyun MD 1,2,3; Li, Hujun MD 1,2,3; Yan, Zhiling MD 1,2,3; Zhou, Dian MD 1,2,3; Wang, Ying MD 1,2,3; Qi, Yuekun MD 1,2,3; Cao, Jiang MD 1,2,3; Li, Depeng MD 1,2,3; Cheng, Hai MD 1,2,3; Sang, Wei MD 1,2,3; Zhu, Feng MD 1,2,3; Sun, Haiying MD 1,2,3; Chen, Wei MD 1,2,3; Qi, Kunming MD 1,2,3; Yan, Dongmei MD 1,2,3; Qiu, Tingting MD 1,2,3; Qiao, Jianlin PhD 1,3; Yao, Ruosi PhD 1,3; Liu, Yang MD 1,2; Wang, Xue MD 1,2; Zhang, Yanlei MSc 4,; Peng, Shuixiu MSc 4,; Huang, Chih-Hua MSc, MPhil 4,; Zheng, Junnian PhD 5,6; Li, Zhenyu MD 1,2,3; Chang, Alex H. PhD 4,7,; Xu, Kailin MD 1,2,3,
doi : 10.1200/JCO.22.01824
G protein-coupled receptor, class C group 5 member D (GPRC5D) is considered to be a promising surface target for multiple myeloma (MM) immunotherapy.
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
Wang, Yucai MD, PhD 1,; Jain, Preetesh MBBS, MD, DM, PhD 2; Locke, Frederick L. MD 3,; Maurer, Matthew J. DMSc 1,; Frank, Matthew J. MD, PhD 4,; Munoz, Javier L. MD, MS, MBA 5,; Dahiya, Saurabh MBBS 6,; Beitinjaneh, Amer M. MD 7,; Jacobs, Miriam T. MD 8; Mcguirk, Joseph P. MD, PhD 9,; Vose, Julie M. MD 10,; Goy, Andre MD 11,; Andreadis, Charalambos MD, MSCE 12,; Hill, Brian T. MD, PhD 13,; Dorritie, Kathleen A. MD 14,; Oluwole, Olalekan O. MBBS, MPH 15,; Deol, Abhinav MD 16,; Paludo, Jonas MD 1,; Shah, Bijal MD 3,; Wang, Trent DO, MPH 7,; Banerjee, Rahul MD 12,; Miklos, David B. MD 4,; Rapoport, Aaron P. MD 6; Lekakis, Lazaros MD 7; Ghobadi, Armin MD 8,; Neelapu, Sattva S. MD 2,; Lin, Yi MD, PhD 1,; Wang, Michael L. MD 2,; Jain, Michael D. MD, PhD 3,
doi : 10.1200/JCO.22.01797
Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL).
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenstrom's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenstrom's Macroglobulinemia.
Buske, Christian MD 1,; Dimopoulos, Meletios A. MD, PhD 2,; Grunenberg, Alexander MD 3; Kastritis, Efstathios MD 2,; Tomowiak, Cecile MD 4,; Mahe, Beatrice MD 5; Troussard, Xavier MD 6,; Hajek, Roman MD, PhD 7,; Viardot, Andreas MD 3,; Tournilhac, Olivier MD 8,; Aurran, Therese MD 9,; Lepretre, Stephane MD 10; Zerazhi, Hacene MD 11; Hivert, Benedicte MD 12,; Leblond, Veronique MD, PhD 13,; de Guibert, Sophie MD 14,; Brandefors, Lena MD, PhD 15; Garcia-Sanz, Ramon MD 16,; Gomes da Silva, Maria MD 17,; Kimby, Eva MD, PhD 18,; Schmelzle, Birgit MSc 1; Kaszynski, Dajana MSc 1; Dreyhaupt, Jens PhD 19; Muche, Rainer PhD 19; Morel, Pierre MD 20,
doi : 10.1200/JCO.22.01805
Rituximab/chemotherapy is a cornerstone of treatment for Waldenstrom's macroglobulinemia (WM). In addition, bortezomib has shown significant activity in WM.
Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.
Sandhya, Lakshmi MD 1; Devi Sreenivasan, Nirmala MSc 1; Goenka, Luxitaa MSc 1; Dubashi, Biswajit MD, DM 1; Kayal, Smita MD, DM 1; Solaiappan, Manikandan MD 2; Govindarajalou, Ramkumar MD 3; KT, Harichandrakumar PhD, MSc 4; Ganesan, Prasanth MD, DM 1,
doi : 10.1200/JCO.22.01997
Anorexia occurs in 30%-80% of patients with advanced malignancies, which may be worsened with chemotherapy. This trial assessed the efficacy of olanzapine in stimulating appetite and improving weight gain in patients receiving chemotherapy.
ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer.
Van Cutsem, Eric MD, PhD 1,; Taieb, Julien MD, PhD 2,; Yaeger, Rona MD 3,; Yoshino, Takayuki MD 4,; Grothey, Axel MD 5,; Maiello, Evaristo MD 6; Elez, Elena MD, PhD 7,; Dekervel, Jeroen MD 1,; Ross, Paul MD 8,; Ruiz-Casado, Ana MD, PhD 9,; Graham, Janet MD, PhD 10,; Kato, Takeshi MD 11,; Ruffinelli, Jose C. MD 12,; Andre, Thierry MD 13,; Carriere Roussel, Edith PhD 14; Klauck, Isabelle MD 15,; Groc, Melanie MSc 14; Vedovato, Jean-Claude MD 14,; Tabernero, Josep MD, PhD 16,
doi : 10.1200/JCO.22.01693
The positive BEACON colorectal cancer (CRC) safety lead-in, evaluating encorafenib + cetuximab + binimetinib in previously treated patients with BRAFV600E-mutated metastatic CRC (mCRC), prompted the design of the phase II ANCHOR CRC study (ClinicalTrails.gov identifier: NCT03693170).
Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study.
Weil, Brent R. MD, MPH 1,2,; Murphy, Andrew J. MD 3; Liu, Qi MSc 4; Howell, Rebecca M. PhD 5,; Smith, Susan A. PhD 5; Weldon, Christopher B. MD, PhD 1,2,6; Mullen, Elizabeth A. MD 2; Madenci, Arin L. MD, PhD 1,7; Leisenring, Wendy M. PhD 8; Neglia, Joseph P. MD 9; Turcotte, Lucie M. MD 9; Oeffinger, Kevin C. MD 10; Termuhlen, Amanda M. MD 9; Mostoufi-Moab, Sogol MD 11; Levine, Jennifer M. MD 12,; Krull, Kevin R. PhD 13,; Yasui, Yutaka PhD 13; Robison, Leslie L. MD 13; Armstrong, Gregory T. MD, MSc 13,; Chow, Eric J. MD, MPH 8,; Armenian, Saro H. DO 14,15
doi : 10.1200/JCO.22.02111
To evaluate long-term morbidity and mortality among unilateral, nonsyndromic Wilms tumor (WT) survivors according to conventional treatment regimens.
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
de Braud, Filippo MD 1,2,; Dooms, Christophe MD, PhD 3; Heist, Rebecca S. MD, MPH 4,; Lebbe, Celeste MD, PhD 5,; Wermke, Martin MD 6,; Gazzah, Anas MD 7; Schadendorf, Dirk MD 8,; Rutkowski, Piotr MD, PhD 9,; Wolf, Jurgen MD 10,; Ascierto, Paolo A. MD, PhD 11,; Gil-Bazo, Ignacio MD, PhD 12,13,14,15,; Kato, Shumei MD 16,; Wolodarski, Maria MD, PhD 17; McKean, Meredith MD, MPH 18,; Munoz Couselo, Eva MD, PhD 19,20,; Sebastian, Martin MD 21,; Santoro, Armando MD 22,23,; Cooke, Vesselina PhD 24,; Manganelli, Luca PhD 25,; Wan, Kitty PhD 25; Gaur, Anil PhD 26,; Kim, Jaeyeon PhD 24,; Caponigro, Giordano PhD 24,; Couillebault, Xuan-Mai MSc 25; Evans, Helen PhD 27,; Campbell, Catarina D. PhD 24,; Basu, Sumit PhD 28,; Moschetta, Michele MD, PhD 25,; Daud, Adil MBBS 29,
doi : 10.1200/JCO.22.02018
No approved targeted therapy for the treatment of patients with neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS)-mutant melanoma is currently available.
Targeting NRAS Mutations in Advanced Melanoma.
Phadke, Manali S. PhD 1; Smalley, Keiran S.M. PhD 1,2,
doi : 10.1200/JCO.23.00205
What Is the Optimal Way to Use Geriatric Assessment and Patient-Reported Outcomes in Older Patients With Advanced Cancer?.
Kaneko, Takahiro MD; Shimomura, Akihiko MD, PhD; Shimizu, Chikako MD, PhD
doi : 10.1200/JCO.22.02874
Reply to T. Kaneko et al.
Flannery, Marie RN, PhD; Culakova, Eva MS, PhD; Mohile, Supriya MD, MS
doi : 10.1200/JCO.23.00248
Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma.
Huang, Shang-Xiao MD; Luo, Peng-Hui MD; Wang, Han-Lei MD; Mo, Dun-Chang MD; Huang, Jian-Feng MD
doi : 10.1200/JCO.22.02665
Use of Daratumumab in Patients With Previously Treated Multiple Myeloma.
Patel, Ashwin P. MBBS, PhD
doi : 10.1200/JCO.22.02850
Erratum: Postmortem Tissue Donation: Giving Families the Ability to Choose.
doi : 10.1200/JCO.23.00479
